DDAVP Nasal Spray

Desmopressin Acetate (DDAVP)

Product Specs Desmopressin Acetate (DDAVP)
Manufacturer Name CSL Behring
Indications DDAVP (desmopressin acetate), is a treatment used to stop some types of bleeding in people with mild hemophilia A with Factor VIII coagulant activity levels greater than 5% or mild to moderate von Willebrand disease (VWD) Type 1 with Factor VIII coagulant activity levels greater than 5%.
Contraindications Contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of DDAVP. DDAVP is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min). DDAVP is contraindicated in patients with hyponatremia or a history of hyponatremia.
Viral Safety Process N/A
Product Half-Life Range 3.3 to 3.5 hours
Manufacturing Method A synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation
Storage Requirements
  • Refrigerated at 2°C to 8°C (36°F to 46°F) (injectable)
  • Store at room temperature not to exceed 25°C (77°F) for the period indicated by the expiration date on the label (nasal spray)
  • Discard 6 months after being opened.
  • Store bottle in upright position (nasal spray)
  • Shelf Life Listed on label
    Nominal Vial Size & Diluent Volume Nasal Spray: 5 mL bottle with spray pump capable of delivering 10 sprays of 10 mcg
    Injectable: 4 mcg/mL
    Route of Administration Nasal Spray
    Intravenous or Subcutaneous Injection

    Return to Manufacturer Name listing Return to Factor Type listing